Research overview
What is MK-677 (Ibutamoren)?
Ibutamoren is a non-peptide small-molecule agonist of the ghrelin/growth-hormone secretagogue receptor. It is commonly catalogued with peptides but its chemical class and studied oral delivery are different. It is not a substitute for prescription growth hormone.
What has research examined?
A randomized modified-crossover trial in 65 healthy older adults found increased GH/IGF-I and fat-free mass with studied oral MK-677, but no increase in strength or function and no significant reduction in visceral fat. Fasting glucose increased and insulin sensitivity decreased. FDA notes that a separate hip-fracture-recovery trial was terminated early over a possible congestive-heart-failure safety signal.
Biomarker and body-composition measurements are not an anti-aging or performance treatment demonstration. Heart-failure and glucose concerns require more than a supplier label; no amount or use advice is offered.
Research references
- Oral ghrelin mimetic MK-677 in healthy older adults: randomized trialAnnals of Internal Medicine
- Certain bulk substances that may present significant safety risksU.S. Food and Drug Administration
Calculation boundary
The studied MK-677 was an oral small molecule, not a generic peptide powder for syringe reconstitution. FDA highlights a potential congestive-heart-failure safety signal for ibutamoren mesylate.